Five Years Later: Penn-developed CAR T Therapy Shows Long-lasting Remissions in Non-Hodgkin Lymphomas
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine.
Read more